Activity standardization of 32Si at PTB.

Within the scope of the SINCRON project, several 32Si solutions were measured by means of liquid scintillation (LS) counting techniques at PTB to determine the activity concentration. Initial results revealed limited long-term stability of the samples, and a discrepancy between the TDCR method and the CIEMAT/NIST efficiency tracing method was found. In some cases, the sample instability could not be completely avoided but there is evidence that the results of the first measurements which are carried out within a few days after sample preparation can be used for an activity determination, though with increased uncertainty. Various sample compositions were tested, and a systematic study of long-term measurements and further experiments indicates that the sample instability is due to an adsorption-like effect. The discrepancies between the two LS methods were significantly lower when measuring other 32Si solutions. The initially observed discrepancies are likely due to low-energetic radioactive impurities that can be present in some of the 32Si solutions. A spectral analysis supports the thesis that tritium is present in the first solution and even allows a rough quantification of the activity ratio A(3H)/A(32Si/32P). This value allows impurity corrections to be applied, which leads to a noticeable improvement in the agreement between TDCR and CIEMAT/NIST efficiency tracing. Finally, a new LS sample composition with 15 mL Ultima Gold and 1 mL of HCl (0.5 mol/L) was found to yield stable LS samples. The activity determinations presented in this paper represent a fundamental step towards a new 32Si half-life determination in the framework of the SINCHRON project.

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations.

The ß--particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.

Activity standardisation of 161Tb.

161Tb, which emits low-energy ß-- and γ-particles in addition to conversion and Auger electrons, has aroused increased interest for medical imaging and therapy. To support the use of this radionuclide, a161Tb solution was standardised using the ß-γ coincidence technique, as well as the TDCR method. The solution had 4.5·10-3% of 160Tb impurities. Primary coincidence measurements, with plastic or liquid scintillators for beta detection, were carried out using both analogue and digital electronics. TDCR measurements using defocusing, grey filtering and quenching for varying the efficiency were also made. Monte Carlo calculations were used to compute the detection efficiency. The coincidence measurements with analogue electronics and the TDCR show a good consistency, and are compatible with the digital coincidence results within uncertainties. An ampoule of this solution was submitted to the BIPM as a contribution to the international reference system.

Determination of 161Tb half-life by three measurement methods.

The radiolanthanide 161Tb is being studied as an alternative to 177Lu for targeted radionuclide tumor therapy. Both ß--particle emitters show similar chemical behavior and decay characteristics, but 161Tb delivers additional conversion and Auger electron emissions that may enhance the therapeutic efficacy. In this study, the half-life of 161Tb was determined by a combination of three independent measurement systems: reference ionization chamber (CIR, chambre d'ionization de référence), portable ionization chamber (TCIR) and a CeBr3 γ-emission detector with digital electronics. The half-life determined for 161Tb is 6.953(2) days, showing a significant improvement in the uncertainty, which is one order of magnitude lower, with a deviation of 0.91% from the last nuclear data reference value. The previous large uncertainty of the half-life had a direct impact on activity measurements. Now it is no more an obstacle to a primary standardization.